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 Fibromyalgia syndrome (FM) is a complex chronic pain disorder of 
unknown causation associated with debilitating fatigue, unrefreshing sleep, 
cognitive and affective symptoms. There is no biological markers to monitor 
FM progression and no permanent cure for FM. Our aim was to identify 
markers associated with FM and its progression and to evaluate the efficacy 
of a battery of treatments. The study is a treatment trial, open label and single 
centre, with 27 women (41 ± 2 years) diagnosed with FM using the 
Widespread Pain Index (WPI), the Symptom Severity (SS) Scale and the 
Fibromyalgia Impact Questionnaire (FIQ). Anthropometric parameters, 
plasma cytokines values and clinical progression were measured before and 
after two months of a multi-approach treatment. A significant improvement 
was observed after two months of treatment as shown by WPI, SS Scale and 
FIQ. No significant variations were observed, except for the intracellular 
body water parameters, in anthropometric and body composition 
characteristics. Food-induced histaminosis release was observed to cow´s 
milk, egg, fruit, wheat and oily fish. Interleukin-1β (IL-1β) and interleukin-6 
(IL-6) plasma cytokine values were significantly higher in FM. A strong 
positive correlation was observed between the percentage of reduction of 
cytokine levels and the improvement of health status. We propose: i) the 
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existence of different subsets of FM patients; ii) the use of intracellular body 
water and plasma cytokine values as positive markers for FM progression; 
iii) that food-sensitisation could be an important mechanism for FM 
pathogenesis and iv) the use of a multidisciplinary approach for FM 
treatment. 
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Introduction 
 FM is a common chronically painful, frequently disabling disorder of 
unknown origin. Patients have a low pain threshold, stiffness and tenderness, 
fatigue, impaired memory, and depression. Some of them also have 
gastrointestinal problems. Recent epidemiological studies estimate its global 
prevalence at 2–8% with a female/male ratio predominance (Clauw; 2014). 
In Spain, the prevalence of fibromyalgia is approximately 2.4%, being more 
frequent in rural (~4.1%) than in urban settings (~1.7%) (Mas et al., 2008). 
 There is no permanent cure for FM, therefore, adequate symptom 
control should be goal of treatment. The problem is that FM patients respond 
differently to treatments. This is probably due to the different pathogenic 
mechanisms involved in FM. The pathophysiological hallmark is a sensitized 
or hyperactive central nervous system that leads to an increased gain on pain 
and sensory processing (Clauw; 2015). In addition, other pathophysiological 
mechanisms such as mitochondrial dysfunction, oxidative stress, an 
inflammatory component (Sanchez-Dominguez et al., 2015) and 
neuroendocrine disturbances (Neeck, 2002) should be added. Moreover, 
overweight or obese has been associated with an increased risk of FM 
especially among those who also reported low levels of physical activity 
(Mork et al., 2010). For this reason, different medical treatments are used to 
treat FM and the recent guidelines suggest that the optimal treatment consists 
in a multidisciplinary approach with a combination of pharmacological and 
non-pharmacological treatment modalities (Rossi et al., 2015). 
 Another problem is that nowadays FM diagnosis is made solely on 
clinical basis, as no validated biological markers associated with the disease 
have been identified. Thus, identification of markers persistently associated 
with FM will help to effectively diagnose the illness, follow its progression 
and more importantly, to monitor the effects of therapeutic approaches. 
 The aim of this study is to identify markers associated with FM and 
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Materials and Methods 
Study sample and characteristics 
 This study is an interventional clinical trial (treatment trial) open 
label and single centre, that included 27 women aged 41 ± 2 years (range: 
19-67 years) who were diagnosed with FM by an internist from the FM Unit 
of Viamed Santa Ángela de la Cruz Hospital and met the American College 
of Rheumatology Criteria for FM. Exclusion criteria for patients were not 
having other rheumatic disease and/or sever somatic or psychiatric disorders 
such as cancer, sever coronary disease, or schizophrenia. Other exclusion 
criteria were cardiac pacemaker, electrically conductive implants in the 
brain, pregnancy and being younger than 18 years old. All patients were 
assessed by the same researchers to reduce interexaminer error. All the 
participants were informed about the study aims and methodology. In 
addition, all of them signed a written informed consent to participate. The 
study was approved by the Ethics Committee of the University Pablo 
Olavide (Seville, Spain). 
 During the first visit to the FM Unit, FM diagnosis was made, 
together with all tests and studies. This procedure was carried out on two 
separate days, with at least 48h between each session. This was done in order 
to prevent fatigue and flare-ups. Then the treatment was prescribed and 
patients returned to the FM Unit after 66 ± 2 days. Afterwards, FM severity 
was assessed and all tests were performed again, following the same 
procedure as in the first visit. 
 The treatment prescribed consisted on (table 1): i) Ubiquinol (the 
fully reduced form of coenzyme Q10; ii) Nutritional complex containing 
amino acids, vitamins and mineral; iii) Palmitoylethanolamide (PEA); iv) 
Synbiotic health supplement; v) Repetitive transcranial electromagnetic 
stimulation (rTMS); vi) Food exclusion and vii) Physical activity. 
 Concerning rTMS, stimulation sessions occurred once per week for 
eight consecutive weeks. Sessions were scheduled along the day and lasted 
20 min. They occurred inside a Faraday cages to reduce environmental 
electromagnetic interference. Stimulation was delivered via a custom-built 
magnetic stimulator. Briefly, a flexible electroencephalography (EEG) cap 
with 33 stimulation coils was placed over the patient’s head. A digital 
electronic generator fed the same oscillating current of intensity to all coils. 
The current amplitude was 545 μA. Each coil produces a magnetic field of 
approximately 43 nT at a distance of 1 cm and 0.9 nT at a distance of 4 cm. 
A low-frequency (8 Hz) square function was used. The relative fluctuations 
in voltage (noise) around the theoretical square function to be applied were 
approximately 3%.  
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Table 1. Treatment prescription details. 
Treatment Characteristics 
Ubiquinol 200 mg/day single-dose oral during 60 days 
Nutritional complex Single-dose oral, during 60 days. It contains amino acids (arginine, 
methionine and glycine), vitamins (D3, E, C and B12) and minerals 
(magnesium, potassium, phosphorus, calcium and chromium) 
PEA 400 mg/day single-dose oral during 60 days 
Synbiotic It contains probiotics (Bifidobacterium lactis, Lactobacillus 
acidophilus, Lactobacillus plantarum and Lactococcus lactis) and 
prebiotics (inulin) 
rTMS 1 session/week for 8 consecutive weeks, 20 min duration, 545 μA 
current amplitude, 43 nT at 1 cm, 8 Hz frequency 
Food exclusion Milk (100%), Egg (61%), fruit (37%), wheat (32%) and oily fish 
(26%) of patients 
Physical activity 45-minutes walking/twice a week at 60% VO2max 
 
Anthropometrics measurements 
 Height (in centimeters) and weight (in kilograms) were measured 
using a mechanical patient weighing scale with a stadiometer (Seca 711, 
Hamburg, Germany). Total body fat (%), trunk fat (%), total body water 
(Kg), intracellular body water (kg) and phase angle (degrees) were measured 
by means of an eight-polar multifrequency bioimpedanciometer (BIA) 
(Promis Cardiofitness, Cadiz, Spain). Body Mass Index (BMI) was 
calculated by dividing patients´weight (in kilograms) by their height (in 
meters) squared.   
 
Fibromyalgia diagnosis and severity 
 FM diagnosis and severity was assessed using the WPI, the SS Scale 
(Wolfe et al.; 2011) and the Spanish version of the FIQ (Rivera and 
Gonzalez, 2004). 
 
Food-induced histaminosis release test 
 Patient´s heparinized blood was incubated with different food 
allergen extracts (cow´s milk, pork, chicken, beef, white fish, oily fish, egg, 
legumes, wheat, rice, tomato, orange, banana, apple, almond and hazelnut) 
for 30 min, at 37ºC. Then, specific histamine release was stopped by adding 
PBS/Tween at 4ºC. Samples were centrifuged for 15 minutes at 5,000 rpm 
using a refrigerated centrifuge. Extraction and purification of histamine from 
plasma was performed by dialysis (dialyzer membrane C12-24, Axflow, 
Madrid, Spain) and subsequent condensation with O-phthalaldehyde 
solution. Finally, histamine fluorometric measurement was performed at 640 
nm. The threshold of histamine release was defined as the minimum 
concentration of food antigen to induce a 7% net histamine release.  
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Cytokine measurements 
 Whole blood cell was collected into commercially available 
anticoagulant-treated tubes (EDTA-treated). Then, cells are removed from 
plasma by centrifugation for 15 minutes at 2,000 g using a refrigerated 
centrifuge. The resulting supernatant was immediately transferred into clean 
polypropylene tubes and stored at -20ºC.  
 Cytokines were determined from plasma using Multiplex Luminex 
assay (Human Cytokine 10-Plex Panel, Life Technologies, Madrid, Spain) 
according to manufacturer instructions.  
 
Statistical analysis 
 All data are presented as means ± standard error of the mean (SEM). 
All secondary analysis was performed using GraphPad InStat software 
(GraphPad, La Jolla, CA, USA). Analysis of variance (ANOVA) was 
performed to data. Thereafter, a paired and unpaired t-test was undertaken. 
P<0,05 was considered significant. Pearson Product Moment correlation was 
also calculated.  
 
Results 
 Table 2 shows that a very significant improvement was observed 
after two months of treatment. In fact, the three outcomes measured, 
widespread pain index, health status (FIQ) and current pain intensity (SS 
scale) were extremely significant (p< 0.001) after two months of 
intervention. However, due to the complexity of the treatment and the study 
design, it was not possible to really understand the meaning and the 
contribution of the different components of the treatment. 
Table 2. Values of FM diagnostic tests before and after the treatment. 
FM diagnostic tests Before treatment After treatment 
WPI 9.7 ± 0.6 5.7 ± 0.6* 
SS Scale 7.6 ± 0.3 4.5 ± 0.4* 
FIQ 61.6 ± 2.7 39.6 ± 4.0* 
*P< 0.001 before treatment vs after treatment. 
 
 When looking at anthropometric and body composition 
characteristics of the study sample (table 3), before and after treatment, no 
significant variations were observed, except for the intracellular body water 
parameters (p< 0.05). In addition, it was observed that: i) patients´ BMI 
index was within normal range; ii) all patients had a severe intracellular 
dehydration and iii) patients didn´t have cellular damage (measured by phase 
angle).    
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Table 3. Anthropometrics characterizes before and after the treatment. 
Anthropometrics characterizes Before treatment After treatment 
BMI 24.3 ± 1.1 23.2 ± 1.0 
Total body fat (%) 34.4 ± 1.8 33.6 ± 1.6 
Trunk fat (%) 34.6 ± 1.7 33.4 ± 1.6 
Total body water (Kg) 30.3 ± 0.5 29.5 ± 0.5 
Intracellular body water (Kg) 15.1 ± 0.3 14.1 ± 0.3* 
Phase angle (degrees) 4.3 ± 0.1 4.2 ± 0.3 
*P< 0.05 before treatment vs after treatment. 
  
 Food-induced histaminosis release tests showed that patients were 
above threshold values for cow´s milk (100%), egg (61%), fruit (orange, 
banana and apple, 37%), wheat (32%) and oily fish (26%). Due to the fact 
that food exclusion was included within the whole treatment design, it was 
difficult to evaluate the real effect of food exclusion in patients´ 
improvement. 
 Plasma cytokine levels (IL-1β, IL-6 and TNF-α) was performed to 
determine the pathophysiological role of pro-inflammatory cytokines in FM 
treatment and progression. As it is observed in table 4, patients with FM had 
IL-1β and IL-6 plasma values higher than those reported in the literature for 
control subjects (Togo et al., 2009). Moreover, the treatment significantly 
(p< 0.001) decreased both cytokines plasma values. When comparing the 
improvement of health status (FIQ) with interleukins percentage of 
reduction, the Pearson’s correlation between the two variables showed a 
positive Pearson Product Moment correlation of 0.59 between FIQ and IL-1β 
reduction and of 0,62 between FIQ and IL-6 reduction (data not shown). 
Both data indicated a fairly strong relationship between health status 
improvement and cytokines plasma values. 
Table 4. Plasma cytokines values before and after treatment. 
Plasma cytokines levels 
(pg/ml) 
Before treatment After treatment 
IL-1β 24.2 ± 1.4 11.5 ± 0.3* 
Il-6 5.4 ± 0.4 2,2 ± 0.1* 
TNF-α 5.6 ± 0.4 5.3 ± 0.3 
*P< 0.001 before treatment vs after treatment. 
 
Discussion 
 Since 2010, FM is diagnosed according to the criteria stablished by 
The American College of Rheumatology (Wolfe et al.; 2011), while patients 
generally have a normal laboratory profile (Yunus, 2002).  In addition, the 
pathophysiological mechanisms of FM are not well understood and several 
mechanisms have been proposed. However, the existence of different 
subtypes of FM patients with different etiology, clinical characteristics and 
biological markers could help to understand the situation and therefore, to 
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design more appropriate treatments for distinct subgroups. The existence of 
subpopulations of FM patients was already proposed by Caro (1989).   
 In this regard, looking to table 3, we observed that our patients´ group 
has a BMI index within normality. However, it has been described that 
women with a BMI greater than or equal to 25 had a 60% to 70% greater risk 
of developing fibromyalgia, when compared with their thinner counterparts. 
In addition, for a women population, aged 40 years and over, the co-
ocurrence of FM with having chronic diseases, such as obesity, were 
strongly related (Rusu et al., 2015). In addition, our group of patients showed 
a severe intracellular dehydration. We do not know the pathophysiological 
meaning of this finding, however, a significant reduction of dehydration was 
observed after treatment and after patients´ clinical improvement. This raises 
the possibility of using intracellular dehydration as a marker of FM 
progression.  
 Our group of patients also has higher plasma levels of IL-1β and IL-
6. These cytokines values were significantly reduced after treatment and 
after clinical improvement, with a strong correlation. This suggests that, 
within this subgroup of patients, the presence of an inflammatory response 
highlighted a parallel between the clinical symptoms and biological markers. 
 Among the factors suspected of promoting FM are food sensitivities 
and intestinal hyperpermeability (Werbach, 2000). The food-induced 
histaminosis release test showed that the majority of FM patients showed 
sensitisation to cow´s milk, egg, fruit, wheat and oily fish. This sensitisation 
could be increased in the presence of increased intestinal permeability. In 
this regard, central sensitisation has been proposed to contribute to FM 
pathogenesis (Nijs et al., 2012). 
 Finally, the FM patients significantly improved with the treatment, as 
shown by the FM diagnostics tests (table 2). The treatment was composed by 
seven items and we still don´t know the importance and effects of the 
different components of the treatment in our group. Additional research is 
necessary to further elucidate this aspect.  
  
Conclusion 
 Our data indicate the existence of different subsets of FM patients. In 
addition, intracellular body water and plasma cytokine values could be used 
as positive markers for FM progression. Food-sensitisation could be an 
important mechanism for FM pathogenesis. Finally, due to the complexity of 
FM a multidisciplinary approach should be the goal of treatment. 
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